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Abstract
Background: We have demonstrated recently that the tumor-to-blood standard uptake ratio (SUR) is superior to
tumor standardized uptake value (SUV) as a surrogate of the metabolic uptake rate Km of fluorodeoxyglucose (FDG),
overcoming several of the known shortcomings of the SUV approach: excellent linear correlation of SUR and Km from
Patlak analysis was found using dynamic imaging of liver metastases. However, due to the perfectly standardized
uptake period used for SUR determination and the comparatively short uptake period, these results are not
automatically valid and applicable for clinical whole-body examinations in which the uptake periods (T ) are distinctly
longer and can vary considerably. Therefore, the aim of this work was to investigate the correlation between SUR
derived from clinical static whole-body scans and Km-surrogate derived from dual time point (DTP) measurements.
Methods: DTP 18F-FDG PET/CT was performed in 90 consecutive patients with histologically proven non-small cell
lung cancer (NSCLC). In the PET images, the primary tumor was delineated with an adaptive threshold method. For
determination of the blood SUV, an aorta region of interest (ROI) was delineated manually in the attenuation CT and
transferred to the PET image. Blood SUV was computed as the mean value of the aorta ROI. SUR values were
computed as ratio of tumor SUV and blood SUV. SUR values from the early time point of each DTP measurement were
scan time corrected to 75 min postinjection (SURtc). As surrogate of Km, we used the SUR(T ) slope, Kslope, derived from
DTP measurements since it is proportional to the latter under the given circumstances. The correlation of SUV and
SURtc with Kslope was investigated. The prognostic value of SUV, SURtc, and Kslope for overall survival (OS) and
progression-free survival (PFS) was investigated with univariate Cox regression in a homogeneous subgroup (N = 31)
treated with primary chemoradiation.
Results: Correlation analysis revealed for both, SUV and SURtc, a clear linear correlation with Kslope (P < 0.001).
Correlation SUR vs. Kslope was considerably stronger than correlation SUV vs. Kslope (R2 = 0.92 and R2 = 0.69,
respectively, P < 0.001). Univariate Cox regression revealed SURtc and Kslope as significant prognostic factors for PFS
(hazard ratio (HR)= 3.4/P = 0.017 and HR= 4.3/P = 0.020, respectively). For SUV, no significant effect was found.
None of the investigated parameters was prognostic for OS.
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Conclusions: Scan-time-corrected SUR is a significantly better surrogate of tumor FDG metabolism in clinical
whole-body PET compared to SUV. The very high linear correlation of SUR and DTP-derived Kslope (which is
proportional to actual Km) implies that for histologically proven malignant lesions, FDG-DTP does not provide added
value in comparison to the SUR approach in NSCLC.
Keywords: PET, FDG, Tumor-to-blood ratio, SUR
Background
In a recent publication [1], we have demonstrated
that the tumor-to-blood standard uptake ratio (SUR)
is superior to tumor standardized uptake value (SUV)
as a surrogate of the metabolic uptake rate Km of
[18F]fluorodeoxyglucose (FDG), overcoming several of
the known shortcomings [2–6] of the SUV approach.
In that work, we performed dynamic PET scans of
liver metastases and computed lesion Km using the
Patlak method [7, 8] which was compared to lesion
SUV and SUR in the late time frames. For these thus
perfectly standardized uptake periods prior to SUV
and SUR determination, we found that SUR correlated
much better than SUV with the true metabolic rate of
FDG.
However, in clinical oncological PET, variability of
the uptake period is unavoidable [9, 10] which directly
translates into a corresponding variability of the measured
tracer uptake [11]. To avoid this limitation, a method to
reliably correct SUR for variations of the FDG uptake
period by converting SUR to a preselected fixed scan
time point was proposed recently by our group [12]. This
scan-time normalized SUR removes several of the short-
comings of SUV. We found strong evidence in a survival
analysis of 130 patients with esophageal carcinoma that,
consequently, SUR has a higher prognostic value than
SUV [13]. However, these results were achieved in clini-
cal whole-body scans with varying uptake periods. Thus,
our previous results [1] regarding the correlation of SUR
and Km (with perfectly standardized and relatively short
uptake period) are not necessarily valid for static onco-
logical PET with variable uptake times. It remains an
open question whether the improved prognostic value
can actually be related to a linear correlation between
SUR and Km which is superior to that between SUV
and Km.
Therefore, the aim of the present work was to investigate
the correlation of SUV and SUR, respectively, with Km
in clinical whole-body scans. We evaluated 90 dual time
point (DTP) measurements of patients with non-small
cell lung cancer (NSCLC) which were used to derive the
SUR slope Kslope as a surrogate parameter of Km with a
procedure similar to that in [14]. Secondary aim of this
study was to test the prognostic value of SUV and SUR in
comparison to Kslope in a homogeneous subgroup (N =
31) of patients with NSCLC which underwent primary
chemoradiation.
Methods
Assessment of metabolic uptake rate in dual time point
measurement
In [14], we have shown that the metabolic uptake rate
Km of a tumor lesion can be estimated from a DTP mea-
surement using two time points T1 and T2. There, we
interpolated the arterial input function (AIF) ca(t) in the
time window [T1,T2] using a single exponential. While
mono-exponential interpolation is sufficient in the con-
text of [14] and does not require knowledge or assump-
tions concerning the AIF outside the considered DTP time
window, we have shown [12] that the shape of the AIF can
be described globally (i.e., for all times after completion
of the bolus passage) quite accurately by an inverse power
law (i.e., a hyperbola)
ca(t) = A × t−b for t  1 − 2 min p.i. (1)
where, moreover, b seems only modestly variable
(≈ ± 10%) across different investigations. (Precisely
speaking, t in Eq. 1 has to be divided by the chosen time
unit (e.g., 1 min.) to generate a dimensionless number that
can be exponentiated; A then represents the AIF value at
t = 1 time unit.) Utilizing this information offers an alter-
native way of estimating Km (or a proportional surrogate)
from a DTP measurement. An immediate consequence of






entering the Patlak equation [7, 8]
ct(T)
ca(T)
= Km ×(T)+Vr for T  15−20 min p.i.
(3)
(ct , tissue concentration; Vr , apparent volume of distribu-
tion) is given by
(T) = 11 − b × T . (4)
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Recalling that SUR is by definition equal to the left-hand
side of Eq. 3, the Patlak equation can be rewritten as
SUR(T) = Km1 − b × T + Vr = Kslope × T + Vr , (5)
In other words, if the AIF obeys Eq. 1 with some fixed
value for b, SUR varies linearly with time for a given
Km and Vr . Furthermore, Vr is numerically small and
might be replaced by some group-averaged constant value
V¯r without introducing relevant errors (see [1]). SUR
then also varies linearly with Km (i.e., across different
lesions/investigations/patients) at a given T. Equation 5
thus has two immediate consequence. The first one, as
discussed in [12], is that scan time correction of SURs
from actual measurement time point T to a reference time
T0 is possible according to
SUR(T0) = T0T ×
(
SUR(T) − V¯r
) + V¯r (6)
which allows to use scan-time-corrected SURs as a surro-
gate of Km. The second consequence is that Km is directly
related to the SUR slope,
Km = (1 − b) × Kslope, (7)




T2 − T1 . (8)
If it is permissible to neglect inter- and intra-individual
variability of the shape parameter b (i.e., assuming a
generic AIF shape), we come to the conclusion that
the DTP-derived SUR slope is directly proportional to
Km in an investigation-independent way. Of course, the
above considerations rest on several assumptions whose
validity cannot be taken for granted, especially if results
from previous investigations are applied in a different
context (e.g., different patient groups, much later scan
times). Especially, notable deviations of the AIF from the
assumed/extrapolated hyperbola at late times or violation
of the assumed irreversible kinetics would affect the rela-
tion between instantaneous SUR at some fixed time point
and the DTP-derived SUR slope.
In the present investigation, we therefore want to clarify
the empirical relation between scan-time-corrected SUR
(which is derivable from a standard whole-body investi-
gation) and the SUR slope as derivable from DTP mea-
surements and the extent to which this correlation is in
agreement with the theory presented above according to
which both quantities can serve as essentially equivalent
surrogates of Km.
Patient group
In the present study, 105 consecutive patients with his-
tologically proven NSCLC were included retrospectively.
Evaluation of the data was approved by the Institu-
tional Ethics Committee, and all subjects provided written
informed consent. In all patients, a routine dual time point
FDG PET/CT was performed between March 2011 and
June 2014 prior to treatment (radio(chemo)therapy (RCT)
and/or surgery). Twelve patients were excluded because
of a too short time difference between the two scans
(T< 20 min) which compromises reliable determina-
tion of the DTP-derived SUR slope. Three patients were
excluded because of misalignment of PET and attenuation
CT affecting reliable SUR quantitation (see below). Alto-
gether, 90 subjects were included (70 men, 20 females)
with a mean age of (range) 67 (45–85) years. Validation
of scan time correction of SUR and correlation analysis of
Kslope vs. SUV and SUR, respectively, was performed in
this group.
Survival analysis (see below) was performed in a homo-
geneous subgroup. Inclusion criteria were as follows:
inoperable primary tumor, curative treatment intent,
and no distant metastases. Altogether, 31 subjects were
included in the survival analysis (27 men, 4 females) with
a mean age of (range) 67 (49–85) years. Characteristics of
the tumors are summarized in Table 1.
FDG PET/CT protocol
All patients underwent two hybrid FDG PET/CT. Scans
(3D PET acquisition, 3 min per bed position) were per-
formed with a Biograph mCT 64 (Siemens Medical Solu-
tions Inc., Knoxville, TN, USA). Data acquisition of the
early scan started (65.6 ± 5.54) minutes (range 56.4–79.3)
after injection of (234 ± 9.02) MBq FDG. Acquisition of
the late scans started (123 ± 25.6) minutes postinjection
(p.i.) (range 74.5–197). Time difference between the two
respective scans was on average (52.9 ± 23.8) minutes
(range 20.4–131). All patients had fasted for at least 6 h
Table 1 Tumor characteristics
Characteristics Number (%)
Histology
Squamous cell carcinoma (SCC) 20 (65)
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prior to FDG injection. The serum glucose concentration
measured prior to injection was 6.0mmol/l on average
(range 3.3–10.7). Furosemide (20 mg/2 ml) was injected
intravenously 20 min after FDG application. Tomographic
images were reconstructed using PSF + TOF reconstruc-
tion (2 iterations, 21 subsets). The resulting image data
had a voxel size of 4.1 × 4.1 × 5 mm3.
Image analysis
Coregistration, region of interest (ROI) definition, and
ROI analyses were performed using the ROVER software,
version 3.0.5 (ABX, Radeberg, Germany). Here and in
the following, ROI is used synonymously with “VOI” for
denoting a three-dimensional volume of interest.
For all PET data, the alignment with the attenuation CT
(with focus on the tumor region) was inspected. Data were
excluded when substantial parts of the FDG uptake was
outside the morphological volume as measured in the CT
data.
PET data of the late scan were coregistered to the PET
data of the early scan using rigid body transformations.
Coregistration was restricted to the tumor region plus a
margin of 3–5 cm. Coregistration was visually inspected
using the difference image of the late and early scans
which allows to detect misalignments in the order of
half of a voxel. Alignment was corrected manually when
necessary. This was the case in 5 out of 90 cases.
The metabolically active part of the primary tumor
was delineated in the early scan by an automatic algo-
rithm based on adaptive thresholding taking the local
background into account [15, 16]. The result of the auto-
matic delineation was inspected visually by an experi-
enced observer and corrected manually in case of obvious
segmentation failure. The resulting ROIs were transferred
to the respective late scan (Fig. 1). In both scans, SUVmean
was computed. In the following, the index “mean” is omit-
ted, since only the mean value of lesion SUV/SUR was
considered in the evaluation. Lesion mean rather than
maximum or peak (maximum + immediate vicinity) val-
ues where used since in the special case of DTP mea-
surements, mean values can be determined with higher
accuracy by performing precise coregistration and using
identical delineation in both measurements. The usual
problems typical of lesion mean values (systematic errors
including partial volume effects due to variable delin-
eation) thus affect both time points of the DTP measure-
ment identically which minimizes their adverse effects.
Maximum and peak values on the other hand do have dis-
tinctly higher statistical errors. Therefore, the minimum
required time difference is distinctly larger when using
maximum values which would not have been acceptable
for the present retrospective evaluation of available data.
The arterial blood SUV was determined by defining a
roughly cylindrical aorta ROI in the attenuation CT data
Fig. 1 Representative orthogonal slices of a DTP measurement.
Shown are the early scan (top) and the late scan (bottom). Both scans
were coregistered with emphasis on the alignment of the primary
tumor. The delineation of the tumor was performed in the early scan
and the resulting ROI was transferred to the late scan. ROI boundaries
are depicted inmagenta
which was then transferred to the PET data. To reduce
partial volume effects, a concentric safety margin was
used in the transaxial planes, centering the ROI in the
aorta. Planes showing high tracer uptake close to the aorta
(pathological or otherwise) were excluded. The minimum
volume of the aorta ROI was 5 ml. Blood SUV was com-
puted as mean SUV of the aorta ROI. The DTP pairs of
blood SUVs were separately analyzed regarding consis-
tency with the assumption of an invariant AIF shape (see
Appendix).
SUR was computed as ratio of lesion SUV and blood
SUV. Kslope was computed according to Eq. (8). SUR val-
ues from the early time point of each DTP measurement
(SUR1) were scan time corrected to T0 = 75min (SURtc)
using Eq. (6). The early time points were chosen since they
correspond closely to the uptake times typical for static
whole body investigations.
The performance of scan time correction was assessed
by mean ± standard deviation (SD) of the fractional dif-
ference of SUR between late (SUR2) and early (SUR1) scan
(δSUR = (SUR2 − SUR1)/SUR1) before and after apply-
ing scan time correction to SUR2 from T2 to T1. Linear
correlation analysis of SUV and, respectively, SURtc vs.
Kslope was performed and visualized through scatterplots.
Correlations were compared using a two-tailed z-test of
the corresponding (Fisher transformed) correlation coef-
ficients.
Survival analysis
Survival analysis was performed in the patient subgroup
described above (N = 31). In this group, the associ-
ation of the overall survival (OS) and progression-free
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survival (PFS) with SUV, SURtc, and Kslope was analyzed
using univariate Cox proportional hazard regression in
which the PET parameters were included as binarized
parameters. The cutoffs used for binarization were cal-
culated by performing an univariate Cox regression for
each measured value. The value leading to the hazard
ratio (HR) with the highest significance was used as cutoff.
The probability of survival was computed and rendered as
Kaplan-Meier curves, and samples were compared using a
log-rank test.
Statistical significance was assumed at a P value of less
than 0.05. Statistical analysis was performed with the R
language and environment for statistical computing [17]
version 3.1.2.
Results
Measured SURs are depicted in Fig. 2. The two respec-
tive DTPmeasurements (black circles) are connected with
solid lines. The dashed lines represent linear extrapola-
tions to T = 0 yielding individual estimates of Vr whose
average is V¯r = (−0.35 ± 0.83)ml/ml. Consequently, the
minor influence of a finite Vr might be neglected and
V¯r = 0 be used during scan time correction of SUR (Eq. 6)
which thus reduces to SUR(T0) = T0/T × SUR(T).
δSur of the uncorrected values (i.e., the fractional
difference between actually measured SUR2 and SUR1
of the DTP pairs) showed the expected strong depen-
dency on T with a large average value of (73 ± 34) %
(Fig. 3). After scan time correction of SUR2 from T2
to T1, the difference is essentially removed resulting in
δSUR = (1.5 ± 7.6)%. Correlation analysis revealed for
both, SUV and SURtc, a clear linear correlation with Kslope
(P < 0.001). Correlation SURtc vs. Kslope was consid-
erably stronger than correlation SUV vs. Kslope(R2 =
0.92 and R2 = 0.69, respectively, P < 0.001). While
SURtc thus correlates highly with Kslope (and by impli-
cation with Km) (Fig. 4b), this is not the case for SUV
(Fig. 4a) where large deviations from the regression line
do occur.
In survival analysis (N = 31), univariate Cox regres-
sion revealed SURtc and Kslope as significant prognostic
factors for PFS (HR= 3.4/P = 0.017 and HR= 4.3/P =
0.020, respectively). For SUV, no significant effect was
found (Table 2). Corresponding Kaplan-Meier curves are
shown in Fig. 5. None of the investigated parameters was
prognostic for OS.
Discussion
In this work, we investigated the correlation of SUV and
scan-time-corrected SUR with the DTP-derived rate of
SUR increase (SUR-slope), Kslope. Accepting the results
provided in the Appendix together with those of our
previous studies [1, 12] as sufficient evidence for an
essentially invariant hyperbolic AIF shape described by a
Fig. 2 SURs as derived from the DTP measurements. Black error bars
indicate estimated statistical errors derived by Gaussian error
propagation when assuming a statistical accuracy of 5% for blood
SUVs and 2% for the tumor SUVs. Solid lines connect the respective
first and second time points of the DTP measurements. Dashed lines
represent linear extrapolations back to T = 0 yielding the individual
Vr estimates for the respective DTP measurements. The red point and
error bars are the mean and standard deviation of these Vr estimates.
At the given level of accuracy, results are compatible with Eq. 5
according to which SUR(T ) follows straight lines which approximately
converge at a common point (0, V¯r )
Fig. 3 The fractional difference δSUR between the first and second
time points of each DTP measurement. δSUR of the actual values (the
fractional difference between measured SUR2 and SUR1 of the DTP
pairs) is shown in red. δSUR after scan time correction of SUR2 from T2
to T1 is depicted in blue
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Fig. 4 Correlation of SUV vs. Kslope (a) and of SURtc vs. Kslope (b)
unique value of the exponent b valid for the whole inves-
tigated patient group, Kslope is a proportional measure of
Km. The main result of the current analysis is that SURtc
correlates significantly better with Kslope (and thus Km)
than is the case for SUV.
This finding is a direct consequence of the behavior
apparent in Fig. 2 which demonstrates—in accordance
with Eq. 5—that with good accuracy, all DTP-derived SUR
pairs can be described by straight lines with quite small
y-axis intercepts (parameter Vr in Eq. 5). While our pre-
vious results [1] yielded a mean of V¯r ≈ 0.53 ml/ml, the
data in Fig. 2 suggest rather to use V¯r = 0 ml/ml in the
evaluation (which we did in the present paper). It should
be emphasized that the precise choice for the (numeri-
cally small) value of V¯r is of no major importance: using
the previous best estimate V¯r = 0.53 ml/ml in the present
investigation would just lead to a small bias of six percent-
age points in the computation of the scan-time-corrected
δSUR (blue points in Fig. 3) without any notable effect on
the SURtc vs. Kslope correlation and the survival analysis.
We further note that there is a visible negative correla-
tion between SUR slope (and thus Km) and Vr in Fig. 2
(correlation coefficient r = −0.75), i.e., Vr tends to be
smaller for larger Km, which also is to be expected on the-
oretical grounds. This correlation leads to a shift of the
approximate point of convergence of the different straight
lines. From a purely phenomenological point of view, this
time shift might be accounted for in the equation relating
SURtc and Kslope (while adjusting V¯r accordingly) but we
prefer to avoid this ad hoc approach and instead just use
Table 2 Univariate Cox regression with respect to PFS
Parameter Risk HR 95% CI P value
SUV >7.6 2.4 0.8–7.3 0.11
SURtc >4 3.4 1.2–9.3 0.017
Kslope >0.046 (ml/min/ml) 4.3 1.3–14.7 0.020
the V¯r = 0 approximation. This is perfectly adequate as
demonstrated by our results.
Regarding the SURtc vs. Km correlation, the current
results are of comparable quality to that observed in [1]
(R2 = 0.92 compared to R2 = 0.96), where the correlation
of SUR and Km as derived from Patlak analysis of dynamic
studies up to 60 min p.i. was investigated (see Figure 4
in [1]). Our results are also in accord with previous find-
ings by Hunter et al. which used a somewhat different but
ultimately mostly equivalent approach [18] as well as with
a recent study by Grecchi et al. [19] which demonstrates
the much improved correlation of SUR—referred to as
“ratio method” in that paper—with Km compared to that
of SUV vs. Km in a different context, namely patients with
acute lung injury. The present study further supports the
observation that SURtc is a better surrogate of tumor FDG
metabolism than SUV. In the current analysis, we espe-
cially demonstrated validity of this assumption for later
times points p.i. (and in a different tumor entity).
This finding is also in accord with the performed sur-
vival analysis. While there was no significant effect for
SUV, both SURtc and Kslope were significant prognostic
factors for PFS with comparable effect size. Since it is clear
that the sample size available for this analysis (N = 31)
is far too small for conclusive results, further investiga-
tions will be necessary to clarify this point. Nevertheless,
our results still are an indication that the increased cor-
relation of SURtc with Kslope compared to SUV translates
into an increased prognostic value. Since SURtc and Kslope
showed almost the same prognostic value, it can be stated
that for histologically proven NSCLC DTP measurements
seem not to provide additional information compared
to SURtc analysis of static whole-body scans. We pre-
sume that this conclusion is generally valid as long as no
large deviations from irreversible FDG kinetics are to be
expected.
Our analysis rests on the assumption that the AIF can
be described by a hyperbola (Eq. 1). Therefore, the results
Hofheinz et al. EJNMMI Research  (2016) 6:53 Page 7 of 9
























log−rank: P  = 0.099
























log−rank: P  = 0.012






















Kslope ≤ 0.046 ml/min/ml
Kslope > 0.046 ml/min/ml




Fig. 5 a–c Kaplan-Meier curves with respect to PFS
regarding scan time correction (Fig. 3) are of special inter-
est. Scan time correction will work correctly only if the
AIF can be described by a power law. Our results thus
strongly support this assumption. To some extent, this was
already shown in [12]. Here, we were able to confirm these
results in a larger patient group and for a larger range of
uptake periods.
As has already been explained, Kslope is a proportional
substitute of the actual Km across different investigations
and patients if the AIF follows Eq. 1 with a unique value of
the exponent b, i.e., the shape need not only be hyperbolic
but also be invariant across investigations. The actual
numerical value taken on by b is irrelevant as long as one is
not interested in quantitatively derivingKm fromKslope (or
SURtc). It is, however, relevant to ensure that shape invari-
ance of the AIF with a constant b is a valid assumption in
order to compare Kslope or SURtc from different investiga-
tions. Figures 2 and 4b do not allow any direct conclusions
in this respect (and neither does Fig. 3). But the fact that,
indeed, Kslope as well as SURtc perform superior to SUV in
the survival analysis supports the conjecture that the for-
mer two quantities are in fact better correlated with Km
which in turn implies that b ≈ const in the whole patient
group. The detailed analysis of the blood SUV data pre-
sented in the Appendix supports the hypothesis that the
AIF actually adheres to an invariant shape.
Conclusions
Scan-time-corrected SUR is a significantly better surro-
gate of tumor FDG metabolism in clinical whole-body
PET compared to SUV. The very high linear correla-
tion of SUR and DTP-derived Kslope (proportional to the
actual Km) implies that for histologically proven malig-
nant lesions, FDG-DTP does not provide added value in
comparison to the SUR approach in NSCLC. The poten-
tial benefit of DTP for differentiation of malignant and
inflammatory or benign lesions with high uptake should
be established in further studies.
Compliance with ethical standards
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of
the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Informed consent
was obtained from all individual participants included in
the study.
Appendix
The results presented in Fig. 4b, demonstrate a very good
linear correlation of SURtc with Kslope in full accord with
the prediction of Eq. 5. Ultimately, this implies that the
AIF is adequately parameterized by the hyperbola Eq. 1
(scan time correction to some reference time would not
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work otherwise while being a prerequisite of considering
Eq. 5 for a fixed time T and predicting the correlation
Fig. 4b). On the other hand, these results do not allow
any direct conclusion regarding a generic (investigation-
independent constant) value of the power law exponent b
since only the ratio Kslope = Km/(1 − b) appears in Eq. 5
and Km is not known a priori. But only if b can be assumed
to be constant (and thus the AIF to be shape-invariant)
across different investigations, Kslope (and SURtc) are valid
surrogates of Km when comparing data from different
patients/investigations. Only the fact that Kslope as well
as SURtc indeed perform superior to SUV in the survival
analysis (and thus should be more closely related to Km
and, ultimately, to glucose consumption) provides indirect
evidence for b ≈ const.
The purpose of the present Appendix is to provide
direct evidence that the b ≈ const assumption is valid
for our patient group. For this purpose, Fig. 6 shows the
relative decrease of blood SUV from the first to second
measurements for all DTP pairs. The dashed lines con-
necting both points are the hyperbolas according to Eq. 1.
Blue/red arrows indicate the deviation of the first/second
measurements from the mean hyperbola (corresponding
to the group-averaged b value).
The inset shows the individual b values for all DTP pairs
as well as their mean (blue line) and standard deviation
(dashed red lines). Individual error bars are determined
by Gaussian error propagation using a realistic estimate of
5 % for the statistical accuracy of the separate blood SUV
measurements.
As can be seen, the deviation of the individual blood
SUVs from the mean hyperbola is quite small. The inset,
furthermore, demonstrates, that the standard deviation of
the b value distribution compares favorably with the error
bars of the individual b values. Altogether, the data thus
do not provide any evidence at the given level of measure-
ment accuracy that the individual b values are significantly
different, i.e., the assumption of a common AIF shape (at
least in the accessible time window) is fulfilled in this
patient group. As already explained, this suffices to ensure
that Kslope as well as SURtc can act as accurate surrogates
of Km which in our view is the underlying explanation for
superior performance of both parameters in comparison
to SUV in the survival analysis.
Obviously, knowledge of the actual numerical value of b
is irrelevant (as long as it remains constant across investi-
gations) if one is not interested in quantitatively deriving
Km fromKslope or SURtc.While the actual numerical value
Fig. 6 Pairs of blood SUVs for all DTP measurements. Shown are the ratios of the second to the first value. Dashed lines are the hyperbolas
connecting the pairs. The corresponding b values are shown in the inset. For further details, see Appendix
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of b thus is of no importance for the present paper, it
seems necessary to point out that the average b value
derived from the data in Fig. 6 (b¯ = 0.615 ± 0.153) is
distinctly larger—corresponding to a more pronounced
decrease of the AIF over time—than our previously pub-
lished value b¯ = 0.313 ± 0.030). While the latter value
is more reliable (being based on full, dynamic AIFs) the
underlying data were restricted to times≤60min, whereas
the present data cover distinctly later times after injec-
tion. For the present data, the substantial discrepancy
between both b values still only implies on average a
≈ ±8% change of the first/second blood SUV of the DTP
measurement in comparison to what would have been
expected from the previous results. Presently, it cannot be
ruled out completely that this effect is real (rather than
some unidentified systematic small error in the data such
as contrast-dependence of the scanner’s image recon-
struction software) and that the AIF shape is deviating
from simple hyperbolic behavior beyond 60min p.i. Based
on data from an independent ongoing investigation, we
think this to be improbable but this question deserves
further attention.
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